This conference welcomes a distinguished faculty summarizing the latest data presented at the 2025 American Society of Hematology (ASH) Annual Meeting.

Objectives:

At the end of the session, participants should be able to:

More accurately diagnose and treat various types of benign and malignant hematologic disorders including lymphomas, leukemias and myeloma
Focus on the use of AJCC staging in clinical practice, which includes the use of appropriate prognostic indicators and evidence-based national guidelines used in treatment planning.
Recognize the most recent advances in immunotherapy including CAR T-cell for the treatment of various blood cancers.

Atlantic Health is accredited by the Medical Society of New Jersey to provide continuing medical education credits for physicians.

Atlantic Health designates this live activity for a maximum of 4.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This enduring material:

Was originally released on: 02/28/2026
Was reviewed on: 02/28/2026
Has a termination date of: 02/28/2029

Saad Usmani MD, MBA, FACP, FRCP

Chief, Myeloma Service, Division of Hematologic Malignancies Memorial Sloan Kettering Cancer Center

Appearances